Akebia Therapeutics, INC Form 4 insider transactions

Nicholas Grund, Chief Commercial Officer of Akebia Therapeutics, reports acquisition and disposal of company stock and stock options.

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, reports the acquisition of restricted stock units and stock options.

Director Ronald Frieson exercised stock options to acquire 20,100 shares of Akebia Therapeutics common stock at $0.45 per share on January 17, 2025.

Erik Ostrowski, SVP, CFO, CBO & Treasurer of Akebia Therapeutics, reports the acquisition of 350,000 shares of common stock and 500,000 stock options.

Director Myles Wolf acquired 30,000 shares of common stock and stock options for 45,000 shares of Akebia Therapeutics.

Director Cynthia Smith received 30,000 restricted stock units and options to purchase 45,000 shares of Akebia Therapeutics common stock on June 6, 2024.

Director Michael Rogers acquired 30,000 shares of common stock and options to purchase 45,000 shares of Akebia Therapeutics.

Director Steven C. Gilman received 30,000 restricted stock units and options to purchase 45,000 shares of Akebia Therapeutics common stock on June 6, 2024.

Director Ron Frieson of Akebia Therapeutics received 30,000 restricted stock units and options to purchase 45,000 shares of common stock on June 6, 2024.

Director LeAnne M. Zumwalt reports the acquisition of 30,000 shares of common stock and options to purchase 45,000 shares of Akebia Therapeutics.

Director Adrian Adams acquired 30,000 shares of common stock and options to purchase 45,000 shares of Akebia Therapeutics, Inc.

Nicole R. Hadas, SVP and Chief Legal Officer of Akebia Therapeutics, sold 12,016 shares of common stock on May 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 34,840 shares of common stock on May 13, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc., reported the sale of 27,000 shares of common stock at a price of $1.15 on August 25, 2023.

Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, Inc., reports the sale of 8,661 shares of common stock to cover tax withholding obligations.

Nicole R. Hadas, SVP, Chief Legal Officer of Akebia Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Akebia Therapeutics CEO John P. Butler sold 46,570 shares of common stock on February 29, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc., sold 7,169 shares of common stock on February 29, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Nicole R. Hadas, SVP, Chief Legal Officer of Akebia Therapeutics, Inc., reports the sale of 7,411 shares of common stock on February 27, 2024, to cover tax withholding obligations.

Michel Dahan, SVP and Chief Operating Officer of Akebia Therapeutics, sold 10,744 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc., sold 8,367 shares of common stock on February 27, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Akebia Therapeutics CEO John P. Butler sold 37,733 shares of common stock on February 27, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.